In vivo optical imaging of CD13/APN-expression in tumor xenografts
Authors:
Open Access
- 1 January 2008
- journal article
- research article
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 13 (1) , 011007-9
Abstract
Optical imaging is a desirable technique for in vivo cancer diagnostics since it is a highly sensitive, inexpensive imaging method that can potentially resolve relevant oncological target structures in vivo.1 With the injection of a fluorescent compound (fluorochrome), optical imaging allows specific tagging of particular receptors, antibodies, genes, or drugs, thereby measuring compound biodistribution and pharmacokinetics and hence leading to a better understanding of these processes.1, 2, 3, 4 Combining new quantitative fluorescence imaging methods with target specific fluorochromes facilitates the visualization and quantification of specific receptor expression in vivo. Especially, fluorescence mediated tomography (FMT) as a newly emerging optical imaging technique has been shown to be capable of resolving fluorescence signatures three-dimensionally and quantitatively.5, 6, 7, 8, 9Keywords
This publication has 30 references indexed in Scilit:
- Aminopeptidase N/CD13 targeting fluorescent probes: Synthesis and application to tumor cell imagingPeptides, 2005
- Use of gene expression profiling to direct in vivo molecular imaging of lung cancerProceedings of the National Academy of Sciences, 2005
- Tomographic Fluorescence Mapping of Tumor TargetsCancer Research, 2005
- Validation of in vivo fluorochrome concentrations measured using fluorescence molecular tomographyJournal of Biomedical Optics, 2005
- Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic DrugsAnnals of the New York Academy of Sciences, 2004
- Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing MotifJournal of Biological Chemistry, 2002
- Fluorescence molecular tomography resolves protease activity in vivoNature Medicine, 2002
- In Vivo Tomographic Imaging of Near-Infrared Fluorescent ProbesMolecular Imaging, 2002
- A doxorubicin–CNGRC-peptide conjugate with prodrug propertiesBiochemical Pharmacology, 2002
- CD13—not just a marker in leukemia typingImmunology Today, 1999